SciSparc (SPRC) Competitors $0.22 -0.01 (-4.20%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SPRC vs. SLRX, SNOA, GTBP, JAGX, CYCN, ABVC, IMNN, VIRX, ATHE, and CANFShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Salarius Pharmaceuticals (SLRX), Sonoma Pharmaceuticals (SNOA), GT Biopharma (GTBP), Jaguar Health (JAGX), Cyclerion Therapeutics (CYCN), ABVC BioPharma (ABVC), Imunon (IMNN), Viracta Therapeutics (VIRX), Alterity Therapeutics (ATHE), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Salarius Pharmaceuticals Sonoma Pharmaceuticals GT Biopharma Jaguar Health Cyclerion Therapeutics ABVC BioPharma Imunon Viracta Therapeutics Alterity Therapeutics Can-Fite BioPharma SciSparc (NASDAQ:SPRC) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Is SPRC or SLRX more profitable? SciSparc's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Salarius Pharmaceuticals N/A -148.63%-110.36% Which has more volatility & risk, SPRC or SLRX? SciSparc has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do analysts recommend SPRC or SLRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ASalarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor SPRC or SLRX? Salarius Pharmaceuticals received 24 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSciSparcOutperform Votes266.67% Underperform Votes133.33% Salarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Do institutionals and insiders believe in SPRC or SLRX? 25.1% of SciSparc shares are held by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 5.5% of Salarius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, SPRC or SLRX? SciSparc has higher revenue and earnings than Salarius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$2.88M0.80-$5.12MN/AN/ASalarius Pharmaceuticals$1.84M1.13-$12.54M-$12.61-0.11 Does the media favor SPRC or SLRX? In the previous week, SciSparc's average media sentiment score of 0.00 equaled Salarius Pharmaceuticals'average media sentiment score. Company Overall Sentiment SciSparc Neutral Salarius Pharmaceuticals Neutral SummarySciSparc beats Salarius Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.31M$6.76B$5.06B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A12.22131.9616.70Price / Sales0.80271.051,683.8276.34Price / CashN/A46.0937.1533.56Price / Book0.025.274.614.98Net Income-$5.12M$151.58M$115.40M$224.69M7 Day Performance-4.16%0.28%-0.26%1.31%1 Month Performance-0.49%14.86%5.74%4.90%1 Year Performance-96.46%36.83%33.81%26.34% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.416 of 5 stars$0.22-4.2%N/A-96.3%$2.31M$2.88M0.004SLRXSalarius Pharmaceuticals0.5397 of 5 stars$1.70+1.8%N/A-76.0%$2.45M$1.84M-0.1320Positive NewsGap UpSNOASonoma Pharmaceuticals0.6131 of 5 stars$2.95-1.7%N/A+1,400.8%$2.83M$12.73M-0.29180Upcoming EarningsGTBPGT Biopharma0.3058 of 5 stars$3.28-0.6%N/A-64.8%$4.65MN/A0.008Upcoming EarningsGap DownJAGXJaguar Health0.9179 of 5 stars$1.12-0.8%N/A-94.5%$5.50M$10.19M0.0050CYCNCyclerion Therapeutics0.8876 of 5 stars$3.44+8.9%N/A+26.1%$9.32M$1.62M0.0030Upcoming EarningsGap UpHigh Trading VolumeABVCABVC BioPharmaN/A$0.74flatN/A-43.6%$9.19M$136,396.00-0.4530Gap UpIMNNImunon3.3796 of 5 stars$0.97+0.8%$14.00+1,337.4%-7.8%$9.16M$500,000.00-0.5133Upcoming EarningsVIRXViracta Therapeutics3.2397 of 5 stars$0.22-5.9%$5.50+2,413.7%-71.5%$8.63MN/A-0.1920Positive NewsGap DownHigh Trading VolumeATHEAlterity Therapeutics2.6704 of 5 stars$1.17+1.7%$4.00+241.9%-51.3%$8.54MN/A0.0010Positive NewsCANFCan-Fite BioPharma1.3764 of 5 stars$2.35-2.5%$18.00+666.0%-0.7%$8.32M$667,000.00-1.318News Coverage Related Companies and Tools Related Companies SLRX Alternatives SNOA Alternatives GTBP Alternatives JAGX Alternatives CYCN Alternatives ABVC Alternatives IMNN Alternatives VIRX Alternatives ATHE Alternatives CANF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRC) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
